CN107648288A - A kind of hypoglycemic medicine composition and purposes - Google Patents
A kind of hypoglycemic medicine composition and purposes Download PDFInfo
- Publication number
- CN107648288A CN107648288A CN201711083271.8A CN201711083271A CN107648288A CN 107648288 A CN107648288 A CN 107648288A CN 201711083271 A CN201711083271 A CN 201711083271A CN 107648288 A CN107648288 A CN 107648288A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine composition
- hypoglycemic medicine
- bromocriptine
- maltitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to pharmaceutical technology field, specifically discloses a kind of hypoglycemic medicine composition and purposes, by weight fraction meter, is made up of following raw material：5 10 parts of 5 10 parts of bromocriptine, 15 20 parts of Metformin hydrochloride, 5 10 parts of purslane extract, 10 15 parts of maltitol, 0.1 0.5 parts of tartaric acid, 15 parts of Sucralose, 0.1 0.5 parts of magnesium stearate and PVPP.The hypoglycemic medicine composition of the present invention can effectively solve the problem that prior art individually takes the problem of conventional hypoglycemic medicine can not effectively control diabetes B, while has control blood glucose, coordinating protection inner skin cell function, reduces diabetic complication and other effects.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of hypoglycemic medicine composition and purposes.
Background technology
Diabetes (diabetesmellitus, DM) are one group comprehensive as caused by E＆H factor collective effect
Sign, its basic pathology feature be insulin secretion definitely or relative deficiency, or peripheral tissues cause with sugar to insulin insensitivity
Based on metabolic disorder, including fat, a kind of systemic disease of protein metabolism disorder.The clinic of blood glucose control and complication
The multinomial Study of evidence based medicine such as experiment (DCCT), the perspective diabetes study of Britain (UKPDS) have made people to strengthening blood glucose control
The meaning of system is reached common understanding, and blood glucose fluctuation not only can prevent or delay the generation of chronic complicating diseases of diabetes, improve patient's
Quality of life, and the related medical expense of diabetes can be substantially reduced.But in reality diabetic blood glucose fluctuation rate
It is relatively low.Shown according to a statistics, the diabetic that China receives treatment has 2/3 to be not up to therapeutic purpose.With diabetes B
The extension of the course of disease, many patients have been unable to reach merely the target of intensive treatment by OHA, and now insulin is controlled
Treating just turns into the important method of blood glucose fluctuation.But found in clinical treatment, there is also following problem in itself for injection of insulin：
(1) blood glucose during injection can only be reduced, it is impossible to completely by change of blood sugar curve controlled blood glucose；(2) hypoglycemia is easily produced；
(3) Vapor recovery unit of insulin is poor, and absorption difference is up to 52%；(4) complication can not effectively be controlled.
The dopamine receptor that surges of bromocriptine system peptide, selectivity, clinically it is commonly used to treat shaking plasy,
It can be used to prevent as prolactin inhibitors and prevent physiological lactation and adjoint amenorrhoea and do not ovulate.May 6 in 2009
Day, U.S. FDA approval bromocriptine fast-release tablet is used to treat type ii diabetes.Research confirms bromocriptine fast-release tablet single therapy or auxiliary
Help sulfonylureas, melbine to add sulphonylurea therapy, can improve the glycemic control to numerous diabetics, and do not increase painstaking effort
Pipe disease risk, a brand-new therapy approach is provided for diabetic.Preclinical study shows that increase dopaminergic is lived
Property can improve diabetic symptom, daytime increase dopaminergic activity is also important.To diabetic animal studies have shown that daytime
Special time increase dopaminergic activity is to improve diabetic supersession obstacle maximally effective " reset " biology in a physiologically
The effective means of clock.The 1 times a day medication in morning of bromocriptine fast-release tablet, single brief spikes formula DOPA can be produced soon after oral
Amine agonist activity.Blood glucose after bromocriptine morning improvement meals is without increasing plasma insulin concentrations, in medicine substantially from blood
Many hours after being removed in liquid circulation also show effective work of (such as lunch and dinner) glycemic control postprandial to diabetes B
With.Bromocriptine fast-release tablet represents the new way for the treatment of diabetes B.It is first targeting human body DOPA for diabetic
The medicine of amine (chemical mediator of neuron or nerve cell in nervous system) activity.Dopamine agonist bromocriptine increases DOPA
Amine activity.However, the special mechanism that bromocriptine fast-release tablet improves glycemic control in human body is not yet clear, bromocriptine treatment glycosuria
The research and development of disease are that brain dopamine activity is low when being shown in metabolic disease state based on preclinical study, in diabetes B patient
It is mainly that insulin resistance (human body loses the ability of insulin for reducing blood sugar effect) etc. is a variety of to find these factors in vivo
Metabolic dysfunction.Moreover, preclinical shown with dopamine agonist bromocriptine treatment diabetic animal, bromocriptine fast-release tablet is made
For central nervous system, start the control for resetting and improving externally week metabolism.
The content of the invention
In order to solve the above problems, the present invention provides a kind of hypoglycemic medicine composition and purposes, efficiently solves existing skill
Art individually takes the problem of conventional hypoglycemic medicine can not effectively control diabetes B, while has control blood glucose, in coordinating protection
Chrotoplast function, reduce diabetic complication and other effects.
The present invention is only applicable and simple diabetic, there is other diseases or hepatic and kidney function obstacle person disabling.
The technical scheme that the present invention solves above-mentioned technical problem is as follows：A kind of hypoglycemic medicine composition, by weight fraction meter,
It is made up of following raw material：Bromocriptine 5-10 parts, Metformin hydrochloride 15-20 parts, purslane extract 5-10 parts, maltitol
10-15 parts, tartaric acid 0.1-0.5 parts, Sucralose 1-5 parts, magnesium stearate 0.1-0.5 parts and PVPP 5-
10 parts.
On the basis of above-mentioned technical proposal, the present invention can also do following improvement.
Preferably, a kind of hypoglycemic medicine composition, by weight fraction meter, are made up of following raw material：5 parts of bromocriptine, hydrochloric acid
20 parts of melbine, 5 parts of purslane extract, 15 parts of maltitol, 0.5 part of tartaric acid, 4 parts of Sucralose, magnesium stearate 0.2
8 parts of part and PVPP.
Preferably, a kind of hypoglycemic medicine composition, by weight fraction meter, are made up of following raw material：10 parts of bromocriptine, hydrochloric acid
15 parts of melbine, 10 parts of purslane extract, 10 parts of maltitol, 0.3 part of tartaric acid, 5 parts of Sucralose, magnesium stearate
0.1 part and 10 parts of PVPP
Preferably, a kind of hypoglycemic medicine composition, by weight fraction meter, are made up of following raw material：8 parts of bromocriptine, hydrochloric acid
18 parts of melbine, 8 parts of purslane extract, 12 parts of maltitol, 0.3 part of tartaric acid, 3 parts of Sucralose, magnesium stearate 0.5
8 parts of part and PVPP.
Preferably, a kind of hypoglycemic medicine composition, by weight fraction meter, are made up of following raw material：5 parts of bromocriptine, hydrochloric acid
15 parts of melbine, 10 parts of purslane extract, 10 parts of maltitol, 0.3 part of tartaric acid, 5 parts of Sucralose, magnesium stearate
0.1 part and 5 parts of PVPP.
Preferably, a kind of hypoglycemic medicine composition, the extracting method of the purslane extract are as follows：
Step 1：Take dry purslane powder, add etc. sodium hydroxide solution that mass concentration is 2.5-3.5wt% and etc. matter
The ethanol solution that volume fraction is 50-70% is measured, heating makes its boiling, extracts 3-5 times, merges extract solution, recovery wherein ethanol
To without alcohol taste, concentrate is obtained.
Step 2：Polyamide column on this concentrate, the ethanol elution for being 92-97% with volume fraction, it is green and brown to eluent
Color stops, mobile phone eluent, and recovery wherein ethanol obtains purslane extract to without alcohol taste.
The present invention also provides a kind of hypoglycemic medicine composition and is preparing treatment and/or prevention diabetes or diabetic complication
Purposes in medicine.
Preferably, the diabetic complication includes chronic complicating diseases and acute complicationses, and wherein chronic complicating diseases include
Diabetic cardiovascular complications, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetes, diabetes
Cutaneous lesions etc..
Compared with prior art, the beneficial effects of the invention are as follows：
First, purslane extract is a kind of natural insulin sensitizer, and the present composition is by Metformin hydrochloride
It is used in combination with bromocriptine and natural insulin sensitizer, significant synergy in terms of blood glucose is reduced not only is present, and
Urine micro protein content is being reduced, there is also obvious collaboration in terms of improving renal index and reducing the hypertension that diabetes trigger
Effect, effectively reduce the incidence of diabetic complication.
Second, the pharmacological mechanism of several drugses is different, and in the treatment or prevention for diabetes, several drugses are made
Have complementary advantages with mechanism, make medicine in extensive dosage range can cooperative compensating, be not only able to significantly control blood sugar level,
And hypoglycemic is steady, the toxic side effect of medicine exclusive use is reduced.
3rd, because when forming immobilised compound, the dosage of each single medicine is reduced, thus the incidence of drug side-effect
Reduce；On medical expense, reduced due to reducing, and producing when drug dose used is than being used alone with packing cost, therefore,
Medical expense will not only increase, and have decline on the contrary so that the benefit for the treatment of/expense ratio is significantly improved.Therefore patient
Curative compliance is greatly increased, and quality of life is also just obviously improved.
Embodiment
The principles and features of the present invention are described below, and the given examples are served only to explain the present invention, is not intended to limit
Determine the scope of the present invention.
Embodiment 1
A kind of hypoglycemic medicine composition, is counted in parts by weight, including following components：
5 parts of bromocriptine, 20 parts of Metformin hydrochloride, 5 parts of purslane extract, 15 parts of maltitol, 0.5 part of tartaric acid,
8 parts of 4 parts of Sucralose, 0.2 part of magnesium stearate and PVPP.
Wherein, purslane extract is prepared using following methods：
Step 1：Take the sodium hydroxide solution and wait mass body that the mass concentration such as dry purslane powder, addition is 2.5wt%
Fraction is 50% ethanol solution, and heating makes its boiling, extracts 3 times, merges extract solution, recovery wherein ethanol to without alcohol taste,
Obtain concentrate.
Step 2：Polyamide column on this concentrate, it is green and brown color to eluent with the ethanol elution that volume fraction is 97%
Stop, mobile phone eluent, recovery wherein ethanol obtains purslane extract to without alcohol taste.
Preparation technology：Weigh bromocriptine, Metformin hydrochloride, purslane extract, maltitol, the winestone of recipe quantity
Acid, Sucralose and PVPP.Another 60% ethanol for taking Sq, is incorporated in mixed-powder, and mixing is equal
Softwood processed after even, pelletized by 16 mesh sieves, less than 60 DEG C dryings.Whole grain is carried out with 18 mesh sieves after the completion of drying, is sifted out in dry granular
Fine powder, mix, be then mixed evenly again with dry particl, tabletting with the magnesium stearate of sieving, piece weight 0.2g, produced.It is manufactured
Tablet need to use aluminium-plastic bubble plate packing, be kept in dark place.
Embodiment 2
A kind of hypoglycemic medicine composition, is counted in parts by weight, including following components：
10 parts of bromocriptine, 15 parts of Metformin hydrochloride, 10 parts of purslane extract, 10 parts of maltitol, tartaric acid 0.3
Part, 5 parts of Sucralose, 0.1 part of magnesium stearate and 10 parts of PVPP.
Wherein, purslane extract is prepared using following methods：
Step 1：Take the sodium hydroxide solution and wait mass body that the mass concentration such as dry purslane powder, addition is 3.5wt%
Fraction is 50% ethanol solution, and heating makes its boiling, extracts 5 times, merges extract solution, recovery wherein ethanol to without alcohol taste,
Obtain concentrate.
Step 2：Polyamide column on this concentrate, it is green and brown color to eluent with the ethanol elution that volume fraction is 92%
Stop, mobile phone eluent, recovery wherein ethanol obtains purslane extract to without alcohol taste.
Preparation technology：Weigh bromocriptine, Metformin hydrochloride, purslane extract, maltitol, the winestone of recipe quantity
Acid, Sucralose and PVPP.Another 60% ethanol for taking Sq, is incorporated in mixed-powder, and mixing is equal
Softwood processed after even, pelletized by 16 mesh sieves, less than 60 DEG C dryings.Whole grain is carried out with 18 mesh sieves after the completion of drying, is sifted out in dry granular
Fine powder, mix, be then mixed evenly again with dry particl, tabletting with the magnesium stearate of sieving, piece weight 0.2g, produced.It is manufactured
Tablet need to use aluminium-plastic bubble plate packing, be kept in dark place.
Embodiment 3
A kind of hypoglycemic medicine composition, is counted in parts by weight, including following components：
8 parts of bromocriptine, 18 parts of Metformin hydrochloride, 8 parts of purslane extract, 12 parts of maltitol, 0.3 part of tartaric acid,
8 parts of 3 parts of Sucralose, 0.5 part of magnesium stearate and PVPP.
Wherein, purslane extract is prepared using following methods：
Step 1：Take the sodium hydroxide solution and wait mass body that the mass concentration such as dry purslane powder, addition is 3.5wt%
Fraction is 50% ethanol solution, and heating makes its boiling, extracts 5 times, merges extract solution, recovery wherein ethanol to without alcohol taste,
Obtain concentrate.
Step 2：Polyamide column on this concentrate, it is green and brown color to eluent with the ethanol elution that volume fraction is 92%
Stop, mobile phone eluent, recovery wherein ethanol obtains purslane extract to without alcohol taste.
Preparation technology：Weigh bromocriptine, Metformin hydrochloride, purslane extract, maltitol, the winestone of recipe quantity
Acid, Sucralose and PVPP.Another 60% ethanol for taking Sq, is incorporated in mixed-powder, and mixing is equal
Softwood processed after even, pelletized by 16 mesh sieves, less than 60 DEG C dryings.Whole grain is carried out with 18 mesh sieves after the completion of drying, is sifted out in dry granular
Fine powder, mix, be then mixed evenly again with dry particl, tabletting with the magnesium stearate of sieving, piece weight 0.2g, produced.It is manufactured
Tablet need to use aluminium-plastic bubble plate packing, be kept in dark place.
Embodiment 4：
A kind of hypoglycemic medicine composition, is counted in parts by weight, including following components：
5 parts of bromocriptine, 15 parts of Metformin hydrochloride, 10 parts of purslane extract, 10 parts of maltitol, 0.3 part of tartaric acid,
5 parts of 5 parts of Sucralose, 0.1 part of magnesium stearate and PVPP.
Wherein, purslane extract is prepared using following methods：
Step 1：Take the sodium hydroxide solution and wait mass body that the mass concentration such as dry purslane powder, addition is 3.5wt%
Fraction is 50% ethanol solution, and heating makes its boiling, extracts 4 times, merges extract solution, recovery wherein ethanol to without alcohol taste,
Obtain concentrate.
Step 2：Polyamide column on this concentrate, it is green and brown color to eluent with the ethanol elution that volume fraction is 95%
Stop, mobile phone eluent, recovery wherein ethanol obtains purslane extract to without alcohol taste.
Preparation technology：Weigh bromocriptine, Metformin hydrochloride, purslane extract, maltitol, the winestone of recipe quantity
Acid, Sucralose and PVPP.Another 60% ethanol for taking Sq, is incorporated in mixed-powder, and mixing is equal
Softwood processed after even, pelletized by 16 mesh sieves, less than 60 DEG C dryings.Whole grain is carried out with 18 mesh sieves after the completion of drying, is sifted out in dry granular
Fine powder, mix, be then mixed evenly again with dry particl, tabletting with the magnesium stearate of sieving, piece weight 0.2g, produced.It is manufactured
Tablet need to use aluminium-plastic bubble plate packing, be kept in dark place.
Comparative example
A kind of hypoglycemic medicine composition, is counted in parts by weight, including following components：
15 parts of Metformin hydrochloride, 10 parts of maltitol, 0.3 part of tartaric acid, 5 parts of Sucralose, 0.1 part of magnesium stearate and
5 parts of PVPP.
Preparation technology：Weigh Metformin hydrochloride, maltitol, tartaric acid, Sucralose and the poly- second of crosslinking of recipe quantity
Alkene pyrrolidone.Another 60% ethanol for taking Sq, is incorporated in mixed-powder, softwood processed after being well mixed, passes through 16 mesh sieves
Granulation, less than 60 DEG C dryings.Whole grain is carried out with 18 mesh sieves after the completion of drying, sifts out the fine powder in dry granular, the stearic acid with sieving
Magnesium mixes, and is then mixed evenly again with dry particl, tabletting, piece weight 0.2g, produces.Manufactured tablet need to use aluminium-plastic bubble plate packing,
It is kept in dark place.
The test of pesticide effectiveness：
The hypoglycemic medicine composition of present invention implementation 4 is used for the clinical test of diabetic, evaluation the present embodiment 4
The effect of compound preparation.
1st, case selection：
100 diabetics, wherein male patient 46 are chosen, female patient 54, the oldest is 66 years old, minimum
For 42 years old, average age 47 years old, course of disease 1-20, experimental group and control group are randomly divided into, every group of 50 people, patient is without other diseases
Disease or medical history, and hepatic and renal function is normal.
2nd, instructions of taking：
Experimental group takes pharmaceutical composition made from the embodiment of the present invention 1, three times per day, one at a time, takes before the meal, even
Continuous a week after taking.
Control group takes obtained pharmaceutical composition in comparative example of the present invention, three times per day, one at a time, takes before the meal,
Continuous a week after taking.
3rd, curative effect judges：
It is effective：Patient blood glucose recovers to normal level；
Effectively, blood glucose level in patients has declined, but to drop to normal level；
Invalid, blood glucose level in patients is without any downward trend.
4th, test result：
The therapeutic effect contrast of hypoglycemic pharmaceutical composition in this implementation 4 hypoglycemic pharmaceutical composition and comparative example
It is shown in Table 1, total effective rate 88%, inefficiency 12%.Specific data are shown in Table 1.
The test result contrast table of table 1
| It is effective | Effectively | It is invalid | Total effective rate | Inefficiency | |
| Experimental group | 18 | 26 | 6 | 88% | 12% |
| Control group | 16 | 23 | 11 | 78% | 22% |
In summary, the pharmaceutical composition of hypoglycemic made from the embodiment of the present invention 4 can effectively control blood glucose, therapeutic effect
More preferably.
Claims (9)
1. a kind of hypoglycemic medicine composition, it is characterised in that fraction meter by weight, be made up of following raw material：Bromocriptine 5-10 parts,
Metformin hydrochloride 15-20 parts, purslane extract 5-10 parts, maltitol 10-15 parts, tartaric acid 0.1-0.5 parts, trichlorine sugarcane
Sugared 1-5 parts, magnesium stearate 0.1-0.5 parts and PVPP 5-10 parts.
A kind of 2. hypoglycemic medicine composition according to claim 1, it is characterised in that fraction meter by weight, by following original
Material composition：5 parts of bromocriptine, 20 parts of Metformin hydrochloride, 5 parts of purslane extract, 15 parts of maltitol, 0.5 part of tartaric acid, three
8 parts of 4 parts of chlorine sucrose, 0.2 part of magnesium stearate and PVPP.
A kind of 3. hypoglycemic medicine composition according to claim 1, it is characterised in that fraction meter by weight, by following original
Material composition：10 parts of bromocriptine, 15 parts of Metformin hydrochloride, 10 parts of purslane extract, 10 parts of maltitol, 0.3 part of tartaric acid,
10 parts of 5 parts of Sucralose, 0.1 part of magnesium stearate and PVPP.
A kind of 4. hypoglycemic medicine composition according to claim 1, it is characterised in that fraction meter by weight, by following original
Material composition：8 parts of bromocriptine, 18 parts of Metformin hydrochloride, 8 parts of purslane extract, 12 parts of maltitol, 0.3 part of tartaric acid, three
8 parts of 3 parts of chlorine sucrose, 0.5 part of magnesium stearate and PVPP.
A kind of 5. hypoglycemic medicine composition according to claim 1, it is characterised in that fraction meter by weight, by following original
Material composition：5 parts of bromocriptine, 15 parts of Metformin hydrochloride, 10 parts of purslane extract, 10 parts of maltitol, 0.3 part of tartaric acid,
5 parts of 5 parts of Sucralose, 0.1 part of magnesium stearate and PVPP.
6. according to a kind of hypoglycemic medicine composition described in claim any one of 1-5, it is characterised in that the purslane extraction
The extracting method of thing is as follows：
Step 1：Take the sodium hydroxide solution and wait mass body that the mass concentration such as dry purslane powder, addition is 2.5-3.5wt%
Fraction is 50-70% ethanol solution, and heating makes its boiling, extracts 3-5 times, merges extract solution, recovery wherein ethanol to nothing
Alcohol taste, obtain concentrate.
Step 2：Polyamide column on this concentrate, the ethanol elution for being 92-97% with volume fraction, it is that green and brown color stops to eluent
Only, mobile phone eluent, recovery wherein ethanol obtain purslane extract to without alcohol taste.
A kind of a kind of 7. pharmaceutical dosage form of hypoglycemic medicine composition comprising described in claim any one of 1-5, it is characterised in that
Including conventional tablet, bilayer tablet, multilayer tablet, sustained-release tablet, single chamber Dospan, dual chamber Dospan, pore type controlled release
Tablet, sublingual lozenge, oral quick disintegrating tablet, dispersible tablet, enteric coatel tablets, granule, pill, capsulae enterosolubilis, delayed-release tablet, timing/
Position releasing piece, conventional capsule, spansule, controlled release capsule, the capsule containing micropill or small pieces, the pH containing micropill or small pieces according to
Rely type capsule, oral liquid, film or patch.
8. the hypoglycemic medicine composition described in a kind of any one of claim 1-5 is preparing treatment and/or prevention diabetes or sugar
Urinate the purposes in disease complication medicine.
9. purposes according to claim 8, it is characterised in that the diabetic complication includes chronic complicating diseases and acute
Complication, wherein chronic complicating diseases include diabetic cardiovascular complications, diabetic nephropathy, diabetic neuropathy, diabetes
PVR, diabetes, diabetic dermopathy etc..
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711083271.8A CN107648288A (en) | 2017-11-07 | 2017-11-07 | A kind of hypoglycemic medicine composition and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711083271.8A CN107648288A (en) | 2017-11-07 | 2017-11-07 | A kind of hypoglycemic medicine composition and purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107648288A true CN107648288A (en) | 2018-02-02 |
Family
ID=61120588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711083271.8A Withdrawn CN107648288A (en) | 2017-11-07 | 2017-11-07 | A kind of hypoglycemic medicine composition and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107648288A (en) |
-
2017
- 2017-11-07 CN CN201711083271.8A patent/CN107648288A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104349790A (en) | Glucokinase activator compositions for the treatment of diabetes | |
| CN107432869A (en) | Include net double-layer tablets of Metformin hydrochloride and En Gelie and preparation method thereof | |
| CN110339176A (en) | Composition of medicine and preparation method thereof comprising gigue column spit of fland and melbine | |
| CN101181264A (en) | Pharmaceutical composition taking metformin hydrochloride and vigelegting as active component as well as preparing method and uses thereof | |
| JP2011522844A (en) | Composition for reducing blood glucose level and use thereof | |
| CN103933031B (en) | Compound preparation including DPP-4 inhibitor and metformin hydrochloride and preparation method thereof | |
| CN103402506A (en) | Combination for treatment of diabetes mellitus | |
| CN107693555A (en) | A kind of medicine and purposes for treating diabetes | |
| CN102727894B (en) | A kind of pharmaceutical composition and application thereof for the treatment of diabetes and complication thereof | |
| CN1331470C (en) | Method for preparing high stripping-degree hautriwaic glipizide capsule | |
| CN107648288A (en) | A kind of hypoglycemic medicine composition and purposes | |
| CN102836349B (en) | Traditional Chinese medicine composition for treating diabetes and preparation method thereof | |
| CN109528706A (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN106580962B (en) | Metformin and vildagliptin compound tablet and preparation method thereof | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN109260205B (en) | Application of tetrandrine in preparation of medicine for resisting diabetes and hypertension | |
| CN107714761A (en) | A kind of hypoglycemic medicine and purposes | |
| CN113648380A (en) | Composition for treating diabetes | |
| CN112641776A (en) | A pharmaceutical composition containing metformin or its pharmaceutically acceptable salt and Alogliptin or its pharmaceutically acceptable salt as active ingredients | |
| CN107898788A (en) | A kind of hypoglycemic pharmaceutical composition and preparation method thereof | |
| CN104906115A (en) | Melbine and gliquidone compound sustained-release tablet and preparation method thereof | |
| US10322157B2 (en) | Method of treatment of drug-resistance diabetes mellitus | |
| US10149883B1 (en) | Method of treatment of diabetes-inducing kidney failure | |
| CN104546778A (en) | Medical composition of Gliclazide sustained release preparation and preparation method of medical composition | |
| CN106466325B (en) | A kind of drug, composition and its preparation prevented or treat diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180202 |